No Data
HIGHTIDE-B (02511.HK) will hold a Board of Directors meeting on March 28 to review and approve the annual performance.
Gelonghui reported on March 14 that HIGHTIDE-B (02511.HK) announced that the Board of Directors meeting will be held on March 28, 2025 (Friday) to review and approve the audited annual performance of the company and its subsidiaries for the year ended December 31, 2024, and its release, as well as to address Other matters.
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug
HIGHTIDE-B (02511) has completed the patient enrollment for the HTD1801 head-to-head treatment of Dapagliflozin in a phase III clinical trial for type 2 diabetes.
HIGHTIDE-B (02511) announced that the company's independently developed intestinal and hepatic anti-inflammatory and metabolic regulator ursodeoxycholic acid...
HIGHTIDE-B (02511): Gao Liping has been appointed as the joint company secretary.
HIGHTIDE-B (02511) has announced that due to the need to allocate more time to other work arrangements, Yu Li has submitted...
HighTide Therapeutics to Cooperate on Chronic Diseases, Longevity, Anti-Aging With SSY Group
